Compare Stocks: ACTU, VTVT, AARD, and VANI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.73 -3.7%	$6.32	$3.35 ▼ $17.94	$130.21M	3.74	121,692 shs	89,273 shs
ACTU Actuate Therapeutics	$1.37 +5.4%	$1.32	$0.90 ▼ $9.22	$31.22M	0.95	428,970 shs	474,033 shs
VANI Vivani Medical	$1.39 -2.1%	$1.36	$0.92 ▼ $1.92	$128.09M	2.36	191,242 shs	231,119 shs
VTVT vTv Therapeutics	$33.47 +0.2%	$33.05	$18.00 ▼ $44.00	$131.56M	0.29	73,384 shs	20,869 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-3.70%	-13.44%	-21.18%	+55.71%	-29.95%
ACTU Actuate Therapeutics	+5.38%	-18.93%	+22.32%	-27.13%	-84.09%
VANI Vivani Medical	-2.11%	-0.71%	-0.71%	+17.80%	+19.83%
VTVT vTv Therapeutics	+0.21%	+2.04%	+4.40%	+4.14%	+77.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.73 -3.7%	$6.32	$3.35 ▼ $17.94	$130.21M	3.74	121,692 shs	89,273 shs
ACTU Actuate Therapeutics	$1.37 +5.4%	$1.32	$0.90 ▼ $9.22	$31.22M	0.95	428,970 shs	474,033 shs
VANI Vivani Medical	$1.39 -2.1%	$1.36	$0.92 ▼ $1.92	$128.09M	2.36	191,242 shs	231,119 shs
VTVT vTv Therapeutics	$33.47 +0.2%	$33.05	$18.00 ▼ $44.00	$131.56M	0.29	73,384 shs	20,869 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-3.70%	-13.44%	-21.18%	+55.71%	-29.95%
ACTU Actuate Therapeutics	+5.38%	-18.93%	+22.32%	-27.13%	-84.09%
VANI Vivani Medical	-2.11%	-0.71%	-0.71%	+17.80%	+19.83%
VTVT vTv Therapeutics	+0.21%	+2.04%	+4.40%	+4.14%	+77.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.42	Hold	$15.33	167.60% Upside
ACTU Actuate Therapeutics	2.33	Hold	$10.50	666.42% Upside
VANI Vivani Medical	2.25	Hold	$3.75	169.78% Upside
VTVT vTv Therapeutics	2.50	Moderate Buy	$55.83	66.82% Upside

Current Analyst Ratings Breakdown

Latest ACTU, VTVT, AARD, and VANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	VTVT vTv Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/6/2026	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $42.00
7/30/2026	ACTU Actuate Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
7/20/2026	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$6.00
7/16/2026	VTVT vTv Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$49.00 ➝ $57.00
7/7/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	VTVT vTv Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$67.00
6/24/2026	ACTU Actuate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$3.42 per share	N/A
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.04 per share	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.21 per share	N/A
VTVT vTv Therapeutics	$1.02M	129.29	N/A	N/A	$19.96 per share	1.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-71.54%	-64.94%	N/A
ACTU Actuate Therapeutics	-$22.23M	-$0.87	N/A	N/A	N/A	N/A	-346.19%	-178.40%	N/A
VANI Vivani Medical	-$26.61M	-$0.35	N/A	N/A	N/A	N/A	-191.05%	-70.91%	11/12/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)

Latest ACTU, VTVT, AARD, and VANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ACTU Actuate Therapeutics	-$0.21	-$0.20	+$0.01	-$0.20	N/A	N/A
8/13/2026	Q2 2026	VANI Vivani Medical	-$0.0833	-$0.07	+$0.0133	-$0.07	N/A	N/A
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	12.63	12.63
ACTU Actuate Therapeutics	N/A	1.25	1.25
VANI Vivani Medical	N/A	3.25	3.25
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ACTU Actuate Therapeutics	N/A
VANI Vivani Medical	6.78%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
ACTU Actuate Therapeutics	57.98%
VANI Vivani Medical	53.30%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.88 million	17.99 million	N/A
ACTU Actuate Therapeutics	10	24.01 million	10.09 million	N/A
VANI Vivani Medical	20	90.20 million	42.13 million	Optionable
VTVT vTv Therapeutics	9	3.94 million	3.70 million	Not Optionable

ACTU, VTVT, AARD, and VANI Headlines

Recent News About These Companies

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

September 3 at 10:09 AM | theglobeandmail.com

vTv Therapeutics to Participate in September Investor Conferences

September 2 at 8:00 AM | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving Average - Should You Sell?

September 2 at 3:39 AM | marketbeat.com

vTv Therapeutics Inc. Cl A

August 30, 2026 | barrons.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts

August 18, 2026 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for vTv Therapeutics

August 10, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen

August 8, 2026 | marketbeat.com

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | markets.businessinsider.com

vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS

August 6, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Price Target Lowered to $42.00 at HC Wainwright

August 6, 2026 | marketbeat.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 28, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

May 17, 2026 | finance.yahoo.com

Why vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%

May 16, 2026 | aaii.comA

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

May 15, 2026 | zacks.com

vTv Therapeutics Expands At-The-Market Share Program Capacity

May 13, 2026 | tipranks.com

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026 | globenewswire.com

vTv Therapeutics to Participate in Upcoming May Investor Conferences

May 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACTU, VTVT, AARD, and VANI Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$5.73 -0.22 (-3.70%)

As of 09/3/2026 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Actuate Therapeutics NASDAQ:ACTU

$1.37 +0.07 (+5.38%)

As of 09/3/2026 04:00 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Vivani Medical NASDAQ:VANI

$1.39 -0.03 (-2.11%)

As of 09/3/2026 04:00 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

vTv Therapeutics NASDAQ:VTVT

$33.47 +0.07 (+0.21%)

As of 09/3/2026 04:00 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACTU, VTVT, AARD, and VANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACTU, VTVT, AARD, and VANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACTU, VTVT, AARD, and VANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACTU, VTVT, AARD, and VANI Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Actuate Therapeutics NASDAQ:ACTU

Vivani Medical NASDAQ:VANI

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACTU, VTVT, AARD, and VANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACTU, VTVT, AARD, and VANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACTU, VTVT, AARD, and VANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACTU, VTVT, AARD, and VANI Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Actuate Therapeutics NASDAQ:ACTU

Vivani Medical NASDAQ:VANI

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools